Relugolix
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Relugolix
- Relugolix: From Advanced Prostate Cancer to Nephrogenic Syndrome of Inappropriate Antidiuresis
Using the drug-repurposing report template to generate the Relugolix report from the evidence pack.
Relugolix: From Advanced Prostate Cancer to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Relugolix is an oral GnRH receptor antagonist, originally developed for advanced prostate cancer (and, in combination formulations, for hormone-dependent gynaecological conditions). The TxGNN model predicts it may be effective for Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but currently no clinical trials and no published literature support this specific direction — the signal comes from the AI model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Advanced prostate cancer (based on general drug knowledge; not present in EU authorization data) |
| Predicted New Indication | Nephrogenic syndrome of inappropriate antidiuresis |
| TxGNN Prediction Score | 96.13% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known information, Relugolix is an oral, non-peptide GnRH (gonadotropin-releasing hormone) receptor antagonist. It blocks pituitary GnRH receptors, suppressing LH/FSH release and downstream sex hormone (testosterone/estradiol) secretion. Its efficacy in advanced prostate cancer, and in combination products for hormone-dependent gynaecological conditions, has been established through this hypothalamic-pituitary-gonadal (HPG) axis mechanism.
Nephrogenic syndrome of inappropriate antidiuresis (NSIAD) is a rare condition caused by gain-of-function mutations in the renal vasopressin V2 receptor (AVPR2), which leads to constitutive water reabsorption independent of circulating vasopressin (ADH), causing hyponatremia. This is a distinct pharmacological axis (renal water-handling) from the HPG axis targeted by Relugolix.
There is no established mechanistic pathway connecting GnRH receptor antagonism to AVPR2 receptor activity. Combined with the complete absence of supporting clinical trials or literature, this prediction should be interpreted as a knowledge-graph-derived hypothesis rather than a mechanistically or clinically substantiated candidate.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Relugolix currently has no recorded EU marketing authorizations in the evidence pack (market status: Not Marketed, 0 licenses). No product/indication table can be generated from available data.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN model score, with no clinical trials, no literature, and no clear mechanistic link between GnRH receptor antagonism and AVPR2-driven NSIAD. Regulatory and safety data are also entirely missing, so the candidate cannot proceed past the S0/S1 screening stage.
To proceed, the following is needed:
- TFDA/EMA label data — warnings and contraindications (currently a Blocking data gap, DG001)
- Confirmed mechanism of action from DrugBank or primary literature (DG002)
- EU marketing authorization records (license numbers, approved indications, dosage forms)
- Any preclinical or case-level evidence exploring a GnRH–vasopressin pathway interaction, if it exists
- Drug-drug interaction (DDI) data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.